Equities Analysts Set Expectations for Geron Q3 Earnings

Geron Corporation (NASDAQ:GERN) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for Geron in a research note issued to investors on Wednesday, November 5th. HC Wainwright analyst E. Bodnar expects that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.12) EPS, FY2027 earnings at ($0.10) EPS, FY2028 earnings at $0.04 EPS and FY2029 earnings at $0.20 EPS.

Geron (NASDAQ:GERN) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The firm had revenue of $47.23 million for the quarter, compared to the consensus estimate of $55.24 million.

A number of other equities research analysts also recently issued reports on the stock. Needham & Company LLC lowered their target price on shares of Geron from $5.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.64.

Geron Trading Down 0.9%

NASDAQ GERN opened at $1.07 on Monday. The company has a market cap of $682.68 million, a P/E ratio of -8.23 and a beta of 0.57. Geron has a 12 month low of $1.04 and a 12 month high of $4.33. The company has a debt-to-equity ratio of 0.46, a current ratio of 7.87 and a quick ratio of 6.79. The company has a 50-day moving average of $1.29 and a 200-day moving average of $1.35.

Institutional Investors Weigh In On Geron

Several large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Geron by 2.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock valued at $627,000 after buying an additional 8,123 shares during the period. Frisch Financial Group Inc. lifted its holdings in Geron by 84.3% in the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 8,700 shares during the last quarter. E Fund Management Co. Ltd. boosted its stake in Geron by 12.0% in the second quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 9,849 shares during the period. Savant Capital LLC grew its holdings in shares of Geron by 73.8% during the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 11,074 shares during the last quarter. Finally, Ballentine Partners LLC raised its position in shares of Geron by 14.5% during the 3rd quarter. Ballentine Partners LLC now owns 93,971 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 11,887 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.